Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.

NCT NCT01965106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01965106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)
Lead sponsor
Quark Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
July 31, 2015
Enrollment
46 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, angle-closure, primary, acute